source
- Odyssey Therapeutics raises $279 million in IPO, begins Nasdaq tradingOdyssey Therapeutics, a biotech focused on autoimmune diseases, announced that its initial public offering generated $279 million. The company sold about 15.5 million shares and priced the IPO at…
- Neoadjuvant immunotherapy gaining favor for metastatic melanoma, says Dr. SznolDr. Mario Sznol discussed current guidance on using neoadjuvant therapy for patients with advanced melanoma. Patients who have active nodal disease detected by imaging or physical exam are now vie…